Sanofi In-Licenses Three Diabetes Drugs from Korea's Hanmi in $4.2 Billion Deal

Sanofi of France has finalized an agreement to in-license global rights to three long-acting diabetes drugs from Hanmi Pharma of Korea in a deal worth $4.2 billion. Hanmi will receive $435 million upfront and up to $3.8 billion in development and sales milestones. Hanmi is on a roll. Earlier this year, the company out-licensed a novel lung cancer therapeutic to Boehringer Ingelheim for $730 million and sold the rights for an autoimmune drug to Lilly for $690 million. Hanmi retained the right to co-promote the three long-acting diabetes drugs with Sanofi in Korea and China. More details.... Stock Symbols: (NYSE: SNY) (NYSE: LLY) Share this with colleagues: // //